Jaguar Health Financials - Benzinga

Jaguar Health Inc

JAGXNASDAQ

Trade with Public

Trade with Public

$7.70

0.649.07%

In chiusura: Sep 25, 5:00 PM EST

$7.19

-0.51-6.62%

Post-mercato: Sep 25, 7:59 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Rapporto azionario

Jaguar Health Financials

Jaguar Health (JAGX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Jaguar Health Q2 EPS $(15.70) Up From $(358.94) YoY, Sales $1.225M Down From $2.979M YoY

Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(15.70) per share. This is a 95.63 percent increase over losses of $(358.94) per share from the same period last year. The company reported $1.225 million in

Benzinga Newsdesk

PRO
Jaguar Health Q1 EPS $(13.60) Misses $(4.26) Estimate, Sales $20.272M Beat $4.211M Estimate

Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst consensus estimate of $(4.26) by 219.25 percent. This is a 97.67 percent increase over losses of $(584.45) per share

Benzinga Newsdesk

PRO
Jaguar Health Q3 EPS $(6.28) Misses $(5.08) Estimate, Sales $3.083M Miss $3.730M Estimate

Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(6.28) per share which missed the analyst consensus estimate of $(5.08) by 23.62 percent. This is a 76.08 percent increase over losses of $(26.25) per share from

Benzinga Newsdesk

PRO
Jaguar Health Q2 2025 EPS $(10.25) Misses $(7.13) Estimate, Sales $2.979M Miss $3.265M Estimate

Benzinga Newsdesk

Earnings Scheduled For August 14, 2025

Benzinga Insights

Earnings Preview For Jaguar Health

Benzinga Insights

© 2026 Benzinga | All Rights Reserved